Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Basic information
Cell
92,676
Sample
22

Technology
10X Genomics
Omics
scRNA-seq
Source
Bone Marrow

Dataset ID
37586321
Platform
Illumina NovaSeq 6000
Species
Human
Disease
LBCL,Healthy
Age range
51 - 82
Update date
2023-08-15
Summary

Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that delay recovery. While the biological mechanisms of cytokine release syndrome and neurotoxicity have been investigated, the pathophysiology is poorly understood for prolonged cytopenia, defined as grade ≥3 cytopenia lasting beyond 30 days after CAR T infusion. We performed single-cell RNA sequencing of bone marrow samples from healthy donors and rrLBCL patients with or without prolonged cytopenia and identified significantly increased frequencies of clonally expanded CX3CR1hi cytotoxic T cells, expressing high interferon (IFN)-γ and cytokine signaling gene sets, associated with prolonged cytopenia. In line with this, we found that hematopoietic stem cells from these patients expressed IFN-γ response signatures. IFN-γ deregulates hematopoietic stem cell self-renewal and differentiation and can be targeted with thrombopoietin agonists or IFN-γ-neutralizing antibodies, highlighting a potential mechanism-based approach for the treatment of CAR T-associated prolonged cytopenia.

Overall design

Single cell gene expression profiles for 22 bone marrow samples from patients treated with CAR T-cell product, chemotherapy, and healthy donors. Due to patient privacy concerns the raw data is available through the European Genome-Phenome Archive.

Contributors

To be supplemented.

Contact

To be supplemented.

snRNA-Seq
Sample nameSample titleDiseaseGenderAgeSourceTreatmentTechnologyPlatformOmicsSample IDDataset IDAction
No data available